24.07.2019 • News

Sibur and Gazprom Take Control of Poliom

Sibur and Gazprom Take Control of Poliom (c) Gazprom
Sibur and Gazprom Take Control of Poliom (c) Gazprom

Russian giants Sibur and Gazprom have signed a contract to buy out partner Titan Group’s 50% stake in their Poliom PP joint venture. Financial terms were not revealed.

Launched in 2013, Poliom operates one of Russia’s largest PP plants in Omsk with a capacity of 218,000 t/y. In 2014, Poliom became a jv between Sibur (25%), Gazprom Neft (25%) and Titan. Gazprom Neft supplies Poliom with propane and propylene feedstocks from its refinery in Omsk while Sibur distributes the PP end-products in Russia and the CIS.

Poliom will now be owned by Sibgazpolimer, another jv between Sibur and Gazprom Neft. Sibgazpolimer will be the sole stakeholder in Poliom, but the plant will be operated jointly by Sibur and Gazprom Neft.

“Increasing the stake in Poliom is an important milestone in Gazprom Neft’s long-term strategy focused, among other things, on developing the petrochemical production,” said Levan Kadagidze, head of Gazprom Neft’s commercial directorate. “By integrating oil refining and petrochemical assets into our business, we will be able to use the feedstock from our refineries more efficiently to make high value-added products, while also boosting our competitive edge both domestically and internationally through stronger technology ties with Sibur.

Sergey Komyshan, Sibur’s managing board member and executive director, added that the company will focus on developing Poliom and expanding the plant’s range of polymers to meet growing demand.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read